RaDaR
NeoGenomics' personalised blood test for tiny amounts of leftover cancer, tracking up to 48 mutations from the patient's own tumour.
Overview
RaDaR was developed by Inivata (Cambridge, UK), acquired by NeoGenomics in 2021, and received FDA Breakthrough Device designation in 2021 for detecting residual disease and recurrence. Tracking dozens of variants at once lets it reach very low tumour fractions (parts per hundred thousand in validation studies) and it has been used in head and neck, breast and lung cancer cohorts, including the TRACERx-associated work in lung cancer. It is offered as a laboratory-developed test and competes with Signatera, Guardant Reveal and Oncodetect in a market that Medicare coverage decisions largely shape.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- What a result means: as with other MRD tests, detection of tumour DNA in blood predicts relapse months before scans; how to act on it is still being defined in trials.
Latest papers
topQuery for this drug: (TITLE:"RaDaR" OR ABSTRACT:"RaDaR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RaDaR, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductOncodetect
Shares Signatera, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag test.
- ProductResolution ctDx FIRST
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
- Productcobas EGFR Mutation Test v2
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
- ProductLunit INSIGHT MMG
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductGuardant360 CDx
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag test.
- ProductProFound AI (iCAD)
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
- ProductPD-L1 IHC 22C3 pharmDx
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag test.
- ProductTranspara
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.